Kiora Pharmaceuticals Stock Today
| KPRX Stock | USD 3.29 0.11 3.46% |
PerformanceVery Weak
| Odds Of DistressLow
|
Kiora Pharmaceuticals is trading at 3.29 as of the 21st of March 2025; that is 3.46 percent increase since the beginning of the trading day. The stock's open price was 3.18. Kiora Pharmaceuticals has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2015 | Category Healthcare | Classification Health Care |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. The company has 2.97 M outstanding shares of which 72.08 K shares are now shorted by private and institutional investors with about 0.27 trading days to cover. More on Kiora Pharmaceuticals
Moving together with Kiora Stock
Moving against Kiora Stock
Kiora Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsKiora Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kiora Pharmaceuticals' financial leverage. It provides some insight into what part of Kiora Pharmaceuticals' total assets is financed by creditors.
| |||||
Kiora Pharmaceuticals (KPRX) is traded on NASDAQ Exchange in USA. It is located in 332 Encinitas Boulevard, Encinitas, CA, United States, 92024 and employs 12 people. Kiora Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.75 M. Kiora Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.97 M outstanding shares of which 72.08 K shares are now shorted by private and institutional investors with about 0.27 trading days to cover.
Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64.
Check Kiora Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Kiora Pharmaceuticals is $10.75 Million. 30% of Kiora Pharmaceuticals outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Kiora Ownership Details
Kiora Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| U.s. Bancorp | 2024-12-31 | 8.0 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 3.0 | |
| Ubs Group Ag | 2024-12-31 | 2.0 | |
| Activest Wealth Management | 2024-12-31 | 2.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 1.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Sabby Management Llc | 2024-12-31 | 0.0 | |
| Citadel Advisors Llc | 2024-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | |
| Aigh Capital Management, Llc | 2024-12-31 | 255.6 K | |
| Rosalind Advisors, Inc. | 2024-12-31 | 250.6 K |
Kiora Pharmaceuticals Historical Income Statement
Kiora Stock Against Markets
Kiora Pharmaceuticals Corporate Management
| MD MBA | Chief Officer | Profile | |
| Brian Strem | CEO and President | Profile | |
| Melissa Tosca | Ex Fin | Profile | |
| Stefan Sperl | Executive Operations | Profile | |
| MaryJane Rafii | Consultant | Profile | |
| Melissa CPA | Executive Finance | Profile |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.